Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage

Int J Antimicrob Agents. 2020 Jun;55(6):105964. doi: 10.1016/j.ijantimicag.2020.105964. Epub 2020 Apr 3.

Authors

Mark Olsen¹, Sarah E Cook², Vanthida Huang³, Niels Pedersen⁴, Brian G Murphy²

Affiliations

¹ Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA. Electronic address: molsen@midwestern.edu.
² Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA.
³ Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA.
⁴ Center for Companion Animal Health, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA.

No abstract available

MeSH terms

Adenosine Triphosphate / analogs & derivatives
Adenosine Triphosphate / pharmacology
Amodiaquine / pharmacology
Angiotensin-Converting Enzyme 2
Animals
Antiviral Agents / pharmacology*
Betacoronavirus / drug effects*
COVID-19
COVID-19 Drug Treatment
Cats
Central Nervous System / pathology
Central Nervous System / virology
Coronavirus Infections / drug therapy*
Coronavirus, Feline / drug effects*
Feline Infectious Peritonitis / drug therapy*
Humans
Nelfinavir / pharmacology
Pandemics
Peptidyl-Dipeptidase A / drug effects
Pneumonia, Viral / drug therapy*
Protease Inhibitors / pharmacology*
Pyrrolidines / pharmacology
SARS-CoV-2
Sulfonic Acids

Substances

Antiviral Agents
Protease Inhibitors
Pyrrolidines
Sulfonic Acids
Amodiaquine
Adenosine Triphosphate
GS-441524 triphosphate
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2
GC376
Nelfinavir